Denali Therapeutics (DNLI) Enterprise Value (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Enterprise Value data on file, last reported at -$987.7 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 20.75% year-over-year to -$987.7 million in Q1 2026; TTM through Mar 2026 was -$987.7 million, a 20.75% decrease from a year earlier, with the FY2025 full-year figure at -$867.9 million, down 4.27% from the prior year.
• Enterprise Value for Q1 2026 stood at -$987.7 million, down from -$867.9 million in the prior quarter.
• Over the last five years, Enterprise Value for DNLI reached as high as -$817.9 million in Q1 2025 and fell as low as -$1.3 billion in Q4 2022.
• Historically, Enterprise Value has averaged -$1.0 billion across 5 years, with a median of -$957.5 million in 2022.
• On a YoY basis, Enterprise Value climbed as much as 32.24% in 2022 and fell as far as 54.4% in 2022.
• Year by year, Enterprise Value stood at -$1.3 billion in 2022, then climbed by 22.58% to -$1.0 billion in 2023, then advanced by 19.54% to -$832.3 million in 2024, then fell by 4.27% to -$867.9 million in 2025, then retreated by 13.8% to -$987.7 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$987.7 million in Q1 2026, -$867.9 million in Q4 2025, and -$848.2 million in Q3 2025.